Oncopeptides Reports Positive Results from HORIZON Trial of Melflufen Combo
The combination therapy of melflufen (melphalan flufenamide) and dexamethasone continues to be safe and to elicit deep and durable responses in hard-to-treat patients…
Joana Carvalho, PhD, managing science editor — 
Articles by Joana Carvalho
Belantamab Mafodotin Continues to Show Promise in Advanced Myeloma Trials
Belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, continues to show promise when used alone or in combination with other approved therapies to treat…
JNJ-4528 Continues to Show Strong, Durable Responses in Trial
Janssen’s investigational CAR T-cell therapy for multiple myeloma, called JNJ-4528, continues to lead to strong and durable responses in all patients with…
Xpovio Triple Combo Before FDA for Previously Treated Myeloma Patients
Karyopharm Therapeutics is asking that Xpovio (selinexor) be approved with Velcade (bortezomib) and low-dose dexamethasone to treat people with multiple myeloma…
New Under-the-skin Darzalex Formulation Approved in EU
The European Commission (EC) has approved a new under-the-skin (subcutaneous), fixed-dose formulation of Janssen’s Darzalex (daratumumab) for the treatment of adults…
FDA Asks for More Data on Ide-cel as Potential Multiple Myeloma Therapy
The U.S. Food and Drug Administration (FDA) asked for more information from Bristol Myers Squibb and Bluebird Bio as it considers a…
Bristol Myers, Bluebird Bio Seek FDA Approval of Ide-cel to Treat Advanced Multiple Myeloma
Bristol Myers Squibb and Bluebird Bio are seeking U.S. approval of their lead investigational CAR T-cell therapy —…
FDA Approves Sarclisa Combo to Treat Advanced Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc), in combination with Pomalyst (pomalidomide) and dexamethasone,…
Darzalex Combo Leads to Durable Responses in Patients With Advanced Multiple Myeloma, Follow-up Data Show
Janssen‘s Darzalex (daratumumab) in combination with Revlimid (lenalidomide) and dexamethasone continues to lead to strong and durable responses, and…
Advanced Multiple Myeloma Patients Responding to Janssen’s CAR T-cell Therapy, Trial Data Show
Janssen’s investigational CAR T-cell therapy for multiple myeloma, called JNJ-4528 (JNJ-68284528), safely led to early and deep responses in all patients with relapsed or…